$320,923,453
to EMERGENT BIOSOLUTIONS CANADA INC
BOTULISM ANTITOXIN
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Supplies botulism antitoxin for emergency preparedness and response under a contract that began in 2019.
Botulism antitoxin is a critical countermeasure for bioterrorism and natural outbreak response; this 2019 contract received a modification in April 2026.
Emergent BioSolutions is a key domestic supplier of emergency biologics; sustained funding signals reliance on this vendor for strategic stockpile replenishment.
Botulism antitoxin production is a domestic biodefense capability; maintaining U.S. manufacturing reduces dependence on foreign suppliers for critical medical countermeasures.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-19. Cost: $0.003075.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50119C00075_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.